161 related articles for article (PubMed ID: 16500393)
1. Mucosal healing in Crohn's disease: what you see is what you get?
Mahadevan U
Gastrointest Endosc; 2006 Mar; 63(3):443-4. PubMed ID: 16500393
[No Abstract] [Full Text] [Related]
2. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
[TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question.
Blonski W; Lichtenstein GR
Gastrointest Endosc; 2006 Mar; 63(3):493-6. PubMed ID: 16500403
[No Abstract] [Full Text] [Related]
4. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
5. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
6. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
7. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance.
Francis G; Duggan A
Gastroenterology; 2008 Dec; 135(6):2156-7. PubMed ID: 19013168
[No Abstract] [Full Text] [Related]
8. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
9. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
Lawrance IC
J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
[No Abstract] [Full Text] [Related]
10. Timing infliximab therapy in pediatric Crohn's disease.
Kirschner BS; Huo D
Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
[No Abstract] [Full Text] [Related]
11. Immunogenicity of infliximab in Crohn's disease.
Hanauer SB
N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
[No Abstract] [Full Text] [Related]
12. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Kay M; Wyllie R
Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
[No Abstract] [Full Text] [Related]
13. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
14. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Meier J; Sturm A
Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
[No Abstract] [Full Text] [Related]
15. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
Holtmann MH; Galle PR; Neurath MF
Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
[No Abstract] [Full Text] [Related]
16. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
Fanning SB; Chapman G; Yau Y; Leong RW
J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
[No Abstract] [Full Text] [Related]
17. Combination therapy with infliximab and immunomodulators: is the glass half empty?
Deshpande AR; Abreu MT
Gastroenterology; 2008 Jun; 134(7):2161-3. PubMed ID: 18482585
[No Abstract] [Full Text] [Related]
18. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
19. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
Gearry RB; Irving PM
J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
[No Abstract] [Full Text] [Related]
20. Remicade approved for children with Crohn's disease.
FDA Consum; 2006; 40(4):6. PubMed ID: 17245830
[No Abstract] [Full Text] [Related]
[Next] [New Search]
